Saturday, 31 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 12, 2026

I’m 66, have a paid-off house and $100K sitting in cash. Would this be a good time to invest it all in the S&P 500?

View original at finance.yahoo.com
“She also has about $100,000 in cash sitting in a high-yield savings account”
Verbatim excerpt from the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The stock market isn't pricing current events but rather what the world will look like six to 12 months from now

    60% confidence
  • There are concerns that the S&P 500 stock market rally cannot last forever

    60% confidence
  • Investors are betting the Iran conflict will be short-lived and that China can push Tehran toward de-escalation following the Trump-Xi meeting

    60% confidence
  • The S&P 500 is 16.5% above this year's low

    60% confidence
  • A specific unidentified asset will surge 400% in a year; investors should not miss this 'explosion'

    60% confidence
  • The blockade of the Strait of Hormuz has led to the largest oil-supply disruption in history

    60% confidence
  • Nearly 50% of Americans are making one big Social Security mistake that should be fixed immediately

    60% confidence
  • S&P 500 gains have been driven in part by high demand for new data centers to fuel the rapid growth of AI, despite inflation concerns from rising oil prices

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com